Loading
A phase 2/3 trial of Selinexor, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma is a phase 2/3 interventional study registered as NCT04442022 by Karyopharm Therapeutics Inc, with 501 participants planned, started 2020-09-03 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy). Conditions listed: Relapsed/Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Karyopharm Therapeutics, Selinexor, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Dexamethasone, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Rituximab, Monoclonal antibodies, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Shares Rituximab, Monoclonal antibodies, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Shares Rituximab, Gemcitabine, Monoclonal antibodies, Diffuse large B-cell lymphoma.